<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01323270</url>
  </required_header>
  <id_info>
    <org_study_id>B1971010</org_study_id>
    <secondary_id>6108A1-2008</secondary_id>
    <secondary_id>2010-022449-38</secondary_id>
    <nct_id>NCT01323270</nct_id>
  </id_info>
  <brief_title>A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged &gt;=11 to &lt;19 Years.</brief_title>
  <official_title>A Phase 2, Randomized, Placebo-controlled, Single-blind Trial To Assess The Safety, Tolerability, And Immunogenicity Of Repevax(Registered) And Bivalent Rlp2086 Vaccine When Administered Concomitantly In Healthy Subjects Aged &gt;/= 11 To &lt;19 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to look at a new vaccine that might prevent meningococcal disease, and to look
      at the safety of the new vaccine as well as how it is tolerated when given together with
      Repevax. The study will be done in healthy adolescents.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Prespecified Criteria for the Concomitant Antigen</measure>
    <time_frame>1 month after Vaccination 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With at Least One Adverse Event (AE)</measure>
    <time_frame>Vaccination 1 up to 1 month after Vaccination 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration (GMC) for Diphtheria and Tetanus Antigens</measure>
    <time_frame>1 month after Vaccination 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMC for Acellular Pertussis Antigens</measure>
    <time_frame>1 month after Vaccination 1</time_frame>
    <description>Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EU/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) for Poliomyelitis Antigens</measure>
    <time_frame>1 month after Vaccination 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal to (&gt;=) Prespecified Titer Level</measure>
    <time_frame>1 month after Vaccination 3</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunoglobulin G (IgG) Measured by Geometric Mean Titer (GMT)</measure>
    <time_frame>Before vaccination 1, 1 month after Vaccination 2, 3</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Geometric Mean Fold-Rise (GMFR) for IgG</measure>
    <time_frame>Before Vaccination 1, 1 month after Vaccination 2, 3</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">753</enrollment>
  <condition>Meningococcal Vaccine</condition>
  <condition>rLP2086</condition>
  <condition>Repevax</condition>
  <condition>N Meningitidis Serogroup B</condition>
  <condition>Meningitis</condition>
  <arm_group>
    <arm_group_label>rLP2086</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rLP2086 and Repevax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline and Repevax</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline and Repevax</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rLP2086</intervention_name>
    <description>0.5 mL dose, given at 0, 2 and 6 months.</description>
    <arm_group_label>rLP2086</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Repevax</intervention_name>
    <description>0.5 mL dose, given at 0 months.</description>
    <arm_group_label>rLP2086</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>0.5 mL dose, given at 0, 2 and 6 months.</description>
    <arm_group_label>Saline and Repevax</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Repevax</intervention_name>
    <description>0.5 mL dose, given at 0 months.</description>
    <arm_group_label>Saline and Repevax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Evidence of a personally signed and dated informed consent document indicating that
             the parent/legally acceptable representative and/or subject has been informed of all
             pertinent aspects of the study.

          -  Parent/legally acceptable representative and/or subjects who are willing and able to
             comply with scheduled visits, laboratory tests, and other study procedures.

          -  Male or female subject aged ≥11 and &lt;19 years at the time of enrollment.

          -  Available for the entire study period and can be reached by telephone.

          -  Healthy subject as determined by medical history, physical examination, and judgment
             of the investigator.

          -  Has received full series of diphtheria, tetanus, and pertussis (DTP)/DTaP vaccines and
             oral poliomyelitis virus (OPV)/IPV vaccines per country-specific recommendations
             applicable at the time of receipt.

          -  All male and female subjects must agree to practice a form of effective contraception,
             such as barrier contraception (ie, condom plus spermicide, a female condom, diaphragm,
             cervical cap or intrauterine device), implants, injectables, combined oral
             contraceptives or sexual abstinence prior to entering into the study, for the duration
             of the vaccination period and for 28 days after the last study vaccination. For
             Germany: The phrase sexual abstinence is not applicable, with the understanding that
             all male and all female subjects of childbearing potential must practice an effective
             form of contraception during the study.

          -  Negative urine pregnancy test for female subjects.

        Exclusion Criteria:

          -  Previous vaccination with any meningococcal serogroup B vaccine.

          -  Vaccination with any diphtheria, tetanus, pertussis, or poliomyelitis virus vaccine
             within 5 years of the first study vaccination.

          -  A previous anaphylactic reaction to any vaccine or vaccine-related component.

          -  Contraindication to vaccination with diphtheria, tetanus, pertussis, or poliomyelitis
             virus vaccine.

          -  Bleeding diathesis or condition associated with prolonged bleeding time that would
             contraindicate intramuscular injection.

          -  A known or suspected disease of the immune system or those receiving immunosuppressive
             therapy.

          -  History of culture-proven disease caused by Neisseria meningitidis or Neisseria
             gonorrhoeae.

          -  Significant neurological disorder or history of seizure (excluding simple febrile
             seizure).

          -  Receipt of any blood products, including immunoglobulin within 6 months before the
             first study vaccination.

          -  Current chronic use of systemic antibiotics.

          -  Participation in other studies during study participation. Participation in purely
             observational studies is acceptable.

          -  Received any investigational drugs, vaccines or devices within 28 days before
             administration of the first study vaccination.

          -  Any neuroinflammatory or autoimmune condition, including, but not limited to,
             transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results and, in the judgment of the investigator, would make the subject
             inappropriate for entry into this study.

          -  Subjects who are investigational site staff members or subjects who are Pfizer
             employees directly involved in the conduct of the trial.

          -  Subject is a direct descendant (eg, child, grandchild or other family member) of study
             site or Pfizer personnel.

          -  Subject is pregnant or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Espoo Vaccine Research Clinic</name>
      <address>
        <city>Espoo</city>
        <zip>02100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki South Vaccine Research Clinic</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ita-Helsinki Vaccine Research Clinic</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Järvenpää Vaccine Research Clinic</name>
      <address>
        <city>Järvenpää</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokkola Vaccine Research Clinic</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahti Vaccine Research Clinic</name>
      <address>
        <city>Lahti</city>
        <zip>15140</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu Vaccine Research Clinic</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pori Vaccine Research Clinic</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seinäjoki Vaccine Research Clinic</name>
      <address>
        <city>Seinäjoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen Yliopisto University Of Tampere</name>
      <address>
        <city>Tampere</city>
        <zip>33014</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere Vaccine Research Clinic</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vaccine Research Center</name>
      <address>
        <city>Tampere</city>
        <zip>FIN-33014</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku Vaccine Research Clinic</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vantaa Vaccine Research Clinic</name>
      <address>
        <city>Vantaa</city>
        <zip>01300</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. med. Guido Hein, Dr. med. Rainer Lauf</name>
      <address>
        <city>Bad Sobernheim</city>
        <zip>55566</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gerhard Bleckmann Kinder- und Jugendarzt</name>
      <address>
        <city>Baunatal</city>
        <zip>34225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderarzt-Praxis</name>
      <address>
        <city>Bramsche</city>
        <zip>49565</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis fuer Kinder- und Jugendmedizin Dres. Behre, Burgert, Gunkel</name>
      <address>
        <city>Kehl</city>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. med. Sobhi Mahdi Kinderarzt und Jugendmedizin</name>
      <address>
        <city>Luebeck</city>
        <zip>23566</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Michael Vomstein, Hermann Oesterle, Kinder- und Jugendaerzte</name>
      <address>
        <city>Schwaebisch-Hall</city>
        <zip>74523</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Lenz &amp; (Frau) Dr. med. Marin Eggers</name>
      <address>
        <city>Vellmar</city>
        <zip>34246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dres.T. Schmitz, H. Knee, Ch, Wittermann Fachaerztliche</name>
      <address>
        <city>Weilheim</city>
        <zip>82362</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis fuer Kinder und Jugendliche Welzheim</name>
      <address>
        <city>Welzheim</city>
        <zip>73642</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Lekarski</name>
      <address>
        <city>Debica</city>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowski Szpital Specjalistyczny, im. Jana Pawla II</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Salmed</name>
      <address>
        <city>Leczna</city>
        <zip>21-010</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczna Praktyka Lekarska Gravita</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Oddzial Pediatryczny</name>
      <address>
        <city>Lubartow</city>
        <zip>21-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Praktyka Lekarza Rodzinnego Eskulap</name>
      <address>
        <city>Lublin</city>
        <zip>20-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Praktyka Lekarza Rodzinnego Alina Grocka-Wlazlak</name>
      <address>
        <city>Oborniki Slaskie</city>
        <zip>55-120</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny ZOZ nad Matka i Dzieckiem, Przychodnia Wieku Rozwojowego</name>
      <address>
        <city>Poznan</city>
        <zip>61-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZLA Michalkowice Jarosz i Partnerzy</name>
      <address>
        <city>Siemianowice Slaskie</city>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Nasz Lekarz</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital im. Sw. Jadwigi Slaskiej, Oddzial Pediatryczny</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-345</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1971010&amp;StudyName=A%20trial%20to%20assess%20the%20safety%2C%20tolerability%20and%20immunogenicity%20of%20Repevax%20and%20rLP2086%20vaccine%20when%20given%20together%20in%20healthy%20subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2011</study_first_submitted>
  <study_first_submitted_qc>March 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2011</study_first_posted>
  <results_first_submitted>November 21, 2014</results_first_submitted>
  <results_first_submitted_qc>November 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 26, 2014</results_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy adolescents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 753 participants were enrolled in this study. Of these, 4 participants were not randomized but were vaccinated rLP2086 vaccine or Repevax or Saline at Vaccination 1. These participants were included in safety population and not intent-to-treat population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: rLP2086 + Repevax</title>
          <description>Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Saline+Repevax</title>
          <description>Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="373"/>
                <participants group_id="P2" count="376"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="330"/>
                <participants group_id="P2" count="347"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not eligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized, but not vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: rLP2086 + Repevax</title>
          <description>Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month.</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Saline+Repevax</title>
          <description>Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="373"/>
            <count group_id="B2" value="376"/>
            <count group_id="B3" value="749"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Greater than or equal (&gt;=)11-less than (&lt;)14years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                    <measurement group_id="B2" value="215"/>
                    <measurement group_id="B3" value="432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=14 years-&lt;19 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Prespecified Criteria for the Concomitant Antigen</title>
        <time_frame>1 month after Vaccination 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: rLP2086 + Repevax</title>
            <description>Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Saline+Repevax</title>
            <description>Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Prespecified Criteria for the Concomitant Antigen</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.4"/>
                    <measurement group_id="O2" value="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis toxoid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.7"/>
                    <measurement group_id="O2" value="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis filamentous hemagglutinin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis pertactin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis fimbrial agglutinogens types 2+3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6"/>
                    <measurement group_id="O2" value="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus type 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus type 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus type 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Diphtheria: Exact 2-sided confidence interval (based on Chan and Zhang) was reported for the difference in proportions, expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 10%.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>-0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tetanus: Exact 2-sided confidence interval (based on Chan and Zhang) was reported for the difference in proportions, expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 10%.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pertussis toxoid: Exact 2-sided confidence interval (based on Chan and Zhang) was reported for the difference in proportions, expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 10%.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pertussis filamentous hemagglutinin: Exact 2-sided confidence interval (based on Chan and Zhang) was reported for the difference in proportions, expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 10%.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pertussis pertactin: Exact 2-sided confidence interval (based on Chan and Zhang) was reported for the difference in proportions, expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 10%.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pertussis fimbrial agglutinogens types 2+3: Exact 2-sided confidence interval (based on Chan and Zhang) was reported for the difference in proportions, expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 10%.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poliovirus type 1: Exact 2-sided confidence interval (based on Chan and Zhang) was reported for the difference in proportions, expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 10%.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poliovirus type 2: Exact 2-sided confidence interval (based on Chan and Zhang) was reported for the difference in proportions, expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 10%.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Poliovirus type 3: Exact 2-sided confidence interval (based on Chan and Zhang) was reported for the difference in proportions, expressed as a percentage.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority criteria margin was 10%.</non_inferiority_desc>
            <param_type>Percent difference</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentration (GMC) for Diphtheria and Tetanus Antigens</title>
        <time_frame>1 month after Vaccination 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: rLP2086 + Repevax</title>
            <description>Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Saline+Repevax</title>
            <description>Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Diphtheria and Tetanus Antigens</title>
          <units>International Units per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diphtheria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="1.28" upper_limit="1.55"/>
                    <measurement group_id="O2" value="1.5" lower_limit="1.34" upper_limit="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tetanus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" lower_limit="11.50" upper_limit="13.11"/>
                    <measurement group_id="O2" value="12.4" lower_limit="11.52" upper_limit="13.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMC for Acellular Pertussis Antigens</title>
        <description>Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EU/mL)</description>
        <time_frame>1 month after Vaccination 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: rLP2086 + Repevax</title>
            <description>Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Saline+Repevax</title>
            <description>Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month.</description>
          </group>
        </group_list>
        <measure>
          <title>GMC for Acellular Pertussis Antigens</title>
          <description>Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EU/mL)</description>
          <units>EU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pertussis toxoid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1" lower_limit="24.45" upper_limit="30.07"/>
                    <measurement group_id="O2" value="26.5" lower_limit="23.95" upper_limit="29.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis filamentous hemagglutinin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.4" lower_limit="111.15" upper_limit="128.17"/>
                    <measurement group_id="O2" value="122.9" lower_limit="115.14" upper_limit="131.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis pertactin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317.0" lower_limit="285.64" upper_limit="351.80"/>
                    <measurement group_id="O2" value="336.1" lower_limit="305.82" upper_limit="369.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pertussis fimbrial agglutinogens types 2+3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="339.1" lower_limit="296.35" upper_limit="387.94"/>
                    <measurement group_id="O2" value="364.5" lower_limit="320.62" upper_limit="414.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) for Poliomyelitis Antigens</title>
        <time_frame>1 month after Vaccination 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: rLP2086 + Repevax</title>
            <description>Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Saline+Repevax</title>
            <description>Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) for Poliomyelitis Antigens</title>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="337"/>
                <count group_id="O2" value="348"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Poliovirus type 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="662.1" lower_limit="567.36" upper_limit="772.67"/>
                    <measurement group_id="O2" value="672.6" lower_limit="581.87" upper_limit="777.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus type 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="840.5" lower_limit="725.11" upper_limit="974.29"/>
                    <measurement group_id="O2" value="995.8" lower_limit="860.54" upper_limit="1152.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poliovirus type 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2237.4" lower_limit="1945.81" upper_limit="2572.65"/>
                    <measurement group_id="O2" value="2450.1" lower_limit="2152.60" upper_limit="2788.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal to (&gt;=) Prespecified Titer Level</title>
        <time_frame>1 month after Vaccination 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1: rLP2086 + Repevax</title>
            <description>Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Saline+Repevax</title>
            <description>Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level Greater Than or Equal to (&gt;=) Prespecified Titer Level</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="307"/>
                <count group_id="O2" value="330"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PMB80 [A22] 1:16 (N=158, 166)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.6"/>
                    <measurement group_id="O2" value="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2001 [A56] 1:8 (N=148, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2948 [B24] 1:8 (N=157, 170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8"/>
                    <measurement group_id="O2" value="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PMB2707 [B44] 1:8 (N=146, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5"/>
                    <measurement group_id="O2" value="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Immunoglobulin G (IgG) Measured by Geometric Mean Titer (GMT)</title>
        <time_frame>Before vaccination 1, 1 month after Vaccination 2, 3</time_frame>
        <population>A decision was made, a priori, that the hSBA MnB immunogenicity assay will be used instead of the IgG assay originally planned . Therefore only hSBA assay results will be disclosed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: rLP2086 + Repevax</title>
            <description>Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Saline+Repevax</title>
            <description>Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month.</description>
          </group>
        </group_list>
        <measure>
          <title>Immunoglobulin G (IgG) Measured by Geometric Mean Titer (GMT)</title>
          <population>A decision was made, a priori, that the hSBA MnB immunogenicity assay will be used instead of the IgG assay originally planned . Therefore only hSBA assay results will be disclosed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Fold-Rise (GMFR) for IgG</title>
        <time_frame>Before Vaccination 1, 1 month after Vaccination 2, 3</time_frame>
        <population>A decision was made, a priori, that the hSBA MnB immunogenicity assay will be used instead of the IgG assay originally planned . Therefore only hSBA assay results will be disclosed.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: rLP2086 + Repevax</title>
            <description>Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Saline+Repevax</title>
            <description>Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold-Rise (GMFR) for IgG</title>
          <population>A decision was made, a priori, that the hSBA MnB immunogenicity assay will be used instead of the IgG assay originally planned . Therefore only hSBA assay results will be disclosed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With at Least One Adverse Event (AE)</title>
        <time_frame>Vaccination 1 up to 1 month after Vaccination 3</time_frame>
        <population>Summary was performed for participants as per vaccine administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: rLP2086 + Repevax</title>
            <description>Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Saline+Repevax</title>
            <description>Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One Adverse Event (AE)</title>
          <population>Summary was performed for participants as per vaccine administration.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="374"/>
                <count group_id="O2" value="378"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.4"/>
                    <measurement group_id="O2" value="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE reported from Vaccination 1 to 1 month after last administration of investigational product (bivalent rLP2086/saline/Repevax). SAE reported from Vaccination 1 to 6 months after last of investigational product (bivalent rLP2086/saline/Repevax).</time_frame>
      <desc>Events collected on case report form were reported. Summary was performed for participants as per vaccine administration.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: rLP2086 + Repevax</title>
          <description>Randomized to receive rLP2086 at 0-,2-6-month and Repevax at 0-month.</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Saline+Repevax</title>
          <description>Randomized to receive Saline at 0-,2-6-month and Repevax at 0-month.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Syndactyly</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="374"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

